Having trouble accessing articles? Reset your cache.

miR-21 joins the oncogene ranks

Yale University researchers have reported that microRNA-21 is an oncogene that drives the development-and maintenance-of hematological malignancies in mice.1 The team now plans to antagonize the molecule to treat blood cancers and, potentially, solid tumors.

Previous tissue profiling studies have found that multiple tumor types abnormally overexpress miR-21, including hematological malignancies,2,3glioblastomas4 and colorectal, lung, breast and pancreatic cancers.5 The open question was

Read the full 611 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers